Gemcitabine/nab-paclitaxel for pediatric relapsed/refractory sarcomas.
Jonathan L MettsAdina L AlazrakiDana ClarkErnest K AmankwahKaren J Wasilewski-MaskerBradley A GeorgeThomas A OlsonThomas CashPublished in: Pediatric blood & cancer (2018)
Gemcitabine/nab-paclitaxel is a relatively safe regimen with mainly hematologic toxicities. It offers a well-tolerated, palliative option providing clinical benefit in a subset of patients. A phase I trial of this combination is underway.
Keyphrases
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acute lymphoblastic leukemia
- advanced non small cell lung cancer
- acute myeloid leukemia
- clinical trial
- locally advanced
- study protocol
- diffuse large b cell lymphoma
- palliative care
- randomized controlled trial
- multiple myeloma
- radiation therapy
- hodgkin lymphoma
- phase ii
- rectal cancer
- open label
- advanced cancer
- patient reported
- double blind